UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 16, 2025

RAPID MICRO BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**001-40592**	**20-8121647**
(State or other jurisdiction of incorporation or organization)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**
25 Hartwell Avenue, Lexington, MA		**02421**
(Address of principal executive offices)		**(Zip Code)**

978-349-3200
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbols**	**Name of each exchange on which registered**
Class A Common Stock, $0.01 par value per share	RPID	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 **Regulation FD Disclosure.**

On January 16, 2025, Rapid Micro Biosystems, Inc. updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Investor Relations section of its website and a copy of the presentation is furnished as Exhibit 99.1 to this report.

The information furnished under this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 **Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation
104	Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPID MICRO BIOSYSTEMS, INC.

Date: January 16, 2025

By: /s/ Sean Wirtjes
Sean Wirtjes
Chief Financial Officer

43rd Annual J.P. Morgan Healthcare Conference

Rob Spignesi, President & CEO

January 16, 2025

RAPID MICRO BIOSYSTEMS — NASDAQ: RPID



Disclaimers

This presentation has been prepared by Rapid Micro Biosystems, Inc. (the "Company") solely for informational purposes. This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company's guidance, including with respect to the fourth fiscal quarter and full year 2024; the benefits and features of the Company's products and technology, including its Growth Direct platform and rapid sterility offering; the integration of the Company's Growth Direct technology with Lonza's MODA-EM software system; the Company's goal to achieve positive cash flow by the end of 2027 without additional financing, including the revenue and gross margin drivers behind such goal; and the Company's efforts to drive sustainable, long-term growth and shareholder value.

In some cases, you can identify forward-looking statements by terminology such as "outlook," "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow without requiring additional financing; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company's ability to meet its publicly announced guidance and other expectations about its business and operations; the effectiveness of the Company's sales processes; the Company's need to develop new products and adapt to technological changes; the Company's ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company's ability to maintain its manufacturing capabilities; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company's ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility; and the other important factors outlined under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC"), as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com.

Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this presentation to reflect changes since the date of this presentation, except as may be required by law.

The Company has presented preliminary financial results for the fourth fiscal quarter and full year 2024 that have not been audited and are subject to adjustment based on the Company's completion of year-end financial close processes.

Our vision

We are transforming a critical, regulated part of the global pharmaceutical manufacturing process, bringing microbial quality control into the 21st century.

The new standard in microbial quality control

The standard in automating microbial quality control

Rapid Micro Biosystems

2024 REVENUE[1]	GLOBAL SYSTEMS[1]	CUSTOMERS
~$28M Total Revenue	160+ Cumulative Placements	70% Top 20 Global Pharma[2]
~25% Year / Year Growth	135+ Cumulative Validations	100% Approved CAR-T Manufacturers
~$15M Recurring Revenue	~20 Countries	

1. Preliminary and Unaudited for the year ended December 31, 2024
2. By revenue

2024 revenue guidance exceeded with strong fourth quarter

SELECT HIGHLIGHTS

- Record quarterly (Q4) and full year revenue; ninth quarter in a row exceeding / meeting revenue guidance
- Over 160 cumulative Growth Direct systems now placed globally
- Inflected to positive gross margins in Q3 & Q4
- Announced collaboration with Lonza implementing Growth Direct globally to enable end-to-end automation of MQC testing across cell & gene manufacturing network

RESULTS	Q4 2024[1]	FY 2024[1]
Total Revenue	~$8.2M ~30% growth	~$28.1M ~25% growth
Recurring Revenue	~$4.2M	~$15.5M
Systems Placed	6	21
Systems Validated	4	16

1 Preliminary and Unaudited for the year ended December 31, 2024

Challenges in a traditional microbial quality control (MQC) lab

- High volume testing and mandated by regulators
- Insecure and lacking data integrity
- Subjective and prone to human error
- Manual, paper-based and slow

MQC has not kept up with pharma industry innovation

FACTORS DRIVING CHANGE

Scientific and technology innovation + Growing demand for more complex therapies + Faster & leaner manufacturing + Data integrity & security focus + Regulatory scrutiny

TODAY

Discovery & research

High-throughput R&D automation

TODAY

QC & ANALYSIS

TODAY

Bioprocessing & manufacturing

Flexible single use technologies

Introducing the Growth Direct® platform

The only fully automated,
high-**throughput and secure MQC solution…**

Proprietary Consumables

Data & Software

Global Validation & Support Services

THE GROWTH DIRECT® (GD) PLATFORM

…delivering a compelling value proposition

Data Integrity

Supports global quality **regulatory compliance** and improved data handling and management

Operational Efficiency

Enables **faster decision making** by accelerating time to results by 50% or faster compared to the traditional method

Insight & Accuracy

Eliminate human quality control errors, preventing costly recalls and regulatory interventions

Growth Direct® transforms and modernizes MQC

MANUAL WORKFLOW

1. PULL QC TEST FORM	2. FILL OUT ASSAY INFO	3. PREPARE SAMPLES	4. LOAD INCUBATOR	5. PULL SAMPLES	6. PERFORM COUNTS	7. RECORD COUNTS	8. RETURN SAMPLES
9. SHIFT SAMPLES	10. PULL SAMPLES	11. PERFORM COUNTS	12. PERFORM DUAL-READ	13. RECORD COUNTS	14. KEY INTO LIMS	15. DISCARD	RESULTS

- Manual & subject to error
- 15 steps
- 5-14 days to result / test
- Unsecured

GROWTH DIRECT® | AUTOMATED WORKFLOW

1. Prepare sample & automated loading

2. Automated incubation and analysis & Data handling

Results

- Automated & accurate
- 2 steps
- Results in half the time
- Full data integrity

The Growth Direct® System brings MQC into the 21st Century

FACTORS DRIVING CHANGE

Scientific and technology innovation + Growing demand for more complex therapies + Faster & leaner manufacturing + Data integrity & security focus + Regulatory scrutiny

TODAY

Discovery & research

High-throughput R&D automation

TODAY

QC & ANALYSIS

TODAY

Bioprocessing & manufacturing

Flexible single use technologies

Market forces pushing pharma industry to automation

Large and Growing Market

$5B annual recurring revenue + $5B global system opportunity

Regulatory Pressure

Increasing regulatory scrutiny and enforcement around data integrity and quality

Industry Change

Growth in complex biologics, and cell & gene therapies which require faster, more accurate, higher throughput testing capabilities

Sources: FDA, EvaluatePharma, Alliance for Regen. Medicine

Growth strategy focused on
land and expand augmented by innovation



Customer base includes 70% of the top 20 global pharma companies[1] with significant growth potential

CUSTOMER SEGMENTS WITH ESTABLISHED USE

Biologics
Cell & Gene Therapy / CAR-T
CDMO
Personal Care Products
Small Molecules

160+
cumulative systems placed

70%
of top 20 global pharma are customers

100%
of approved CAR-T manufacturers have GD system placed

135+
cumulative systems validated

6M+
cumulative consumables sold

~100
customer manufacturing sites

GLOBAL SITES WITH GROWTH DIRECT SYSTEMS



GROWTH DIRECT APPLICATIONS

Environmental Monitoring
Water Testing
Bioburden Testing
Rapid Sterility Testing

1 By revenue

Collaborating in automated MQC

- Lonza sought an end-to-end, automated solution to streamline MQC testing and get critical cell and gene therapies to patients faster
- Implemented the Growth Direct with Lonza's MODA-EM software module across their cell and gene therapy manufacturing network in North America, Europe and Asia
- Lonza achieved:
  - More accurate testing
  - Faster processing (TTR <72 hrs vs up to 8 days previously)
  - Improved compliance
  - Cost savings
- Sets a clear standard for the industry to emulate
- Lonza publication available on RPID website
  www.rapidmicrobio.com/learning-center/publications

Growth through innovation:

Growth Direct® Rapid Sterility System

	RAPID STERILITY SYSTEM	COMPENDIAL METHOD
Time to Detection (TTD)	As little as 12 hours	3 – 5 Days
Time to Results (TTR)	As little as 1 - 3 Days	14 Days

Strong and consistent revenue growth and margin improvement



Revenue Growth Drivers

- New customer wins
- Drive global deployments at existing customers
- Launch new products and services
- Strong consumable and service growth

Gross Margin Expansion Drivers

- Reduce product costs
- Improve manufacturing efficiency
- Increase service productivity

Focused goal of achieving positive cash flow by the end of 2027 without the need for additional financing

1 Preliminary and Unaudited for the year ended December 31, 2024

Creating the future of rapid, secure MQC automation to drive sustainable, long-term growth and shareholder value

1 By revenue

Thank you